Small companies have received several key approvals from the FDA in 2024. The pharmaceutical industry is also facing challenges, including a looming patent cliff and regulatory changes, which may lead to shifts in company strategies and investments. Additionally, there are ongoing discussions and developments related to various aspects of the industry, including biologics, antibiotics, and rare disease investment.